Revolution Medicines, Inc. filings document a late-stage clinical oncology company focused on RAS-addicted cancers and RAS(ON) inhibitors. Its Form 8-K reports include financial results, clinical-program updates for daraxonrasib and other pipeline candidates, regulatory-related disclosures and material events tied to corporate progress.
The company’s SEC record also covers proxy governance, annual meeting matters, executive compensation, registered securities and capital-structure changes. Disclosures identify Nasdaq-listed common stock and warrants, and material-agreement filings describe convertible senior notes due 2033, related indenture terms and other financing arrangements used to support research and development, administrative expenses and potential commercialization activities.
Revolution Medicines, Inc. borrowed $250.0 million from Royalty Pharma Development Funding, LLC on October 8, 2026, under Tranche A of its senior secured term loan facility, in connection with FDA approval of RASONQUE (daraxonrasib) for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The company paid a $5.0 million draw fee. The floating annual rate is three-month Term SOFR, subject to a 3.50% floor, plus 5.75%; interest is payable quarterly in arrears, and principal is due October 8, 2032.
The company may voluntarily prepay all, but not less than all, of the loan. It elected not to take Tranche 3 under its royalty purchase agreement and did not deliver the notice by October 10, 2026, so it will not receive the potential Tranche 3 purchase price of up to $250.0 million and Royalty Pharma will not receive the related incremental revenue participation right. Up to an additional $500.0 million in loans and up to an additional $500.0 million in purchase price payments remain potentially available, each subject to applicable milestones and conditions in its agreement.
Revolution Medicines, Inc. Chief Development Officer Alan B. Sandler exercised options for 6,000 shares on September 29, 2026, at an exercise price of $58.84 per share, acquiring 6,000 common shares. His reported option position after the exercise covered 161,300 shares.
That day, Sandler also sold 6,309 shares in five transactions: 2,200 at a weighted average of $200.8188, 1,609 at $201.7239, 1,000 at $202.8127, 1,199 at $203.9074, and 301 at $204.7224 per share. All reported transactions were made pursuant to a Rule 10b5-1 trading plan adopted June 30, 2026.
Revolution Medicines, Inc. (RVMD) SVP & General Counsel Jeff Cislini sold 765 shares of common stock on September 25, 2026, at $207.3201 per share. The sale was made pursuant to a Rule 10b5-1 trading plan adopted May 22, 2026. After the transaction, he reported direct holdings of 51,776 shares, including 37,088 restricted stock units.
Revolution Medicines, Inc. (RVMD) officer Alan Sandler reported a proposed sale of 6,309 common shares, with an approximate sale date of September 29, 2026, through Morgan Stanley Smith Barney LLC. The reported aggregate market value is $1,272,777.66. The notice also lists 341 common shares sold during the preceding three months, with an aggregate market value of $67,940.67.
Revolution Medicines, Inc. (RVMD) Chief Global Commercialization Officer Anthony Mancini exercised options for 3,121 common shares on September 25, 2026, at an exercise price of $33.62 per share, then sold 3,121 shares at $200.54 per share. He also sold 587 shares at $200 per share on September 24, 2026. All reported transactions were made under a Rule 10b5-1 trading plan adopted June 11, 2026. The reported option position after the exercise was 93,625 shares.
Anthony Mancini, an officer of Revolution Medicines, Inc., reported a proposed sale of 9,363 common shares, with an aggregate market value of $1,871,289.18 and an approximate sale date of September 25, 2026. The notice states that the shares to be sold were and will be received upon exercise of stock options over the next three months.
Revolution Medicines, Inc. director Elizabeth M. Anderson exercised options for 5,070 common shares on September 22, 2026, at an exercise price of $1.12 per share. She also sold 10,143 common shares that day. Four multi-trade sales had weighted-average prices of $191.8521, $192.5387, $193.4392 and $194.5887 per share; the 100-share sale was reported at $195.1500 per share. The transactions were made under a Rule 10b5-1 trading plan adopted June 23, 2026. Following the option transaction, 1,095 options remained.
Revolution Medicines, Inc. (RVMD) officer Anthony Mancini reported a proposed sale of 587 common shares, with an aggregate market value of $111,964.38, through Morgan Stanley Smith Barney LLC on September 24, 2026. Mancini also reported three common-stock sales during the preceding three months: 1,764 shares on September 18, 2026; 1,774 shares on September 15, 2026; and 15,448 shares on September 10, 2026. The September 18 and September 10 sales are identified as 10b5-1 sales.
Revolution Medicines, Inc. (RVMD) reported that its Chief Global Commercialization Officer, Anthony Mancini, sold 1,764 shares of common stock on September 18, 2026 in a sale described as an open-market or private transaction at $196.94 per share. Following this sale, he held 40,352 shares directly. The filing states the sale was made pursuant to a Rule 10b5-1 trading plan adopted by Anthony Mancini on June 11, 2026.
Revolution Medicines, Inc. (RVMD) director Elizabeth Anderson filed a notice of proposed sale of company common stock under Rule 144. The notice covers up to 15,080 shares to be sold through Morgan Stanley Smith Barney LLC, with an approximate aggregate market value of $2,906,820.80 and a stated sale date of September 22, 2026 on NASDAQ. The shares are to be acquired from the issuer by cash exercise of stock options, and the remark states that the securities were and will be received upon option exercises and sold over the next three months. The filing also reports that 214,336,418 shares of common stock were outstanding.